Early TAVR for patients with asymptomatic severe AS may save money in the long run
Treating asymptomatic patients with TAVR may cost more at first, but it appears to be a wise financial decision as time goes on.
Treating asymptomatic patients with TAVR may cost more at first, but it appears to be a wise financial decision as time goes on.
What's Your Reaction?
